HCC
61 programs · 59 companies
Programs
61
Companies
59
Trials
49
MOAs
37
EGFRiKIF18AiAnti-AβGLP-1agKRASG12CiTROP-2 ADCBTKiCD3xCD20CGRPantJAK1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Phase 2 | KIF18A | ||
| Pexatenlimab | Phase 1/2 | GPRC5D | ||
| ABB-8696 | Phase 3 | BCMA | ||
| NVO-7840 | Phase 2/3 | B7-H3 | ||
| Terasacituzumab | NDA/BLA | IL-23 | ||
| Bemazumab | Phase 1 | VEGF | ||
| Ivosotorasib | Preclinical | CD38 | ||
| ITC-1028 | Phase 2 | BCMA | ||
| Pexaosocimab | NDA/BLA | PLK4 | ||
| Rilufotisoran | NDA/BLA | FXIa | ||
| ROI-1081 | Phase 1/2 | PI3Kα | ||
| IDY-3466 | NDA/BLA | Nectin-4 | ||
| Motatinib | Preclinical | MDM2 | ||
| EME-9677 | Phase 1 | SMN2 | ||
| 209-6556 | Preclinical | GLP-1R | ||
| Zenozumab | Phase 3 | PI3Kα | ||
| CHA-IIT-927 | Phase 1/2 | CD19 | ||
| GIM-IIT-548 | Phase 3 | GIP-R | ||
| CAR-6194 | Preclinical | GLP-1R | ||
| INH-2936 | Phase 2 | PD-L1 | ||
| WIN-5410 | NDA/BLA | AHR | ||
| Ribozanubrutinib | Phase 2/3 | FXIa | ||
| Gelirapivir | NDA/BLA | JAK2 | ||
| DRR-2203 | Phase 2/3 | CDK2 | ||
| Gozelemzoparlimab | Approved | PI3Kα | ||
| Zenonesiran | Preclinical | CD20 | ||
| 195-4808 | Preclinical | TIM-3 | ||
| ALE-9377 | Approved | CD19 | ||
| Niratuximab | Phase 1 | BTK | ||
| Pemifutibatinib | Phase 3 | BET | ||
| Olpasotorasib | Phase 1/2 | WRN | ||
| Nirazumab | Phase 2/3 | WEE1 | ||
| Semarasimod | Phase 1/2 | EZH2 | ||
| Miricilimab | Phase 2 | PD-1 | ||
| GH-3607 | NDA/BLA | PSMA | ||
| Sovazasiran | Phase 1/2 | SOS1 | ||
| Sotocapivasertib | Approved | TIGIT | ||
| Cevirapivir | Approved | SOS1 | ||
| Zorisotorasib | Approved | JAK2 | ||
| 451-4283 | Phase 2 | C5 | ||
| 488-3348 | Phase 2/3 | IL-13 | ||
| MOR-4433 | Phase 1/2 | GLP-1R | ||
| GEN-516 | Phase 2/3 | PLK4 | ||
| Ivozumab | Phase 1 | RET | ||
| Ribotenlimab | NDA/BLA | AuroraA | ||
| Sovasacituzumab | Phase 2 | TIM-3 | ||
| Lisofotisoran | NDA/BLA | FcRn | ||
| Elraosocimab | Phase 3 | Cl18.2 | ||
| PHA-5173 | Phase 3 | TIGIT | ||
| TEV-8109 | Phase 1 | CD20 | ||
| ROY-IIT-152 | Phase 1 | B7-H3 | ||
| Talacagene | Phase 2/3 | AuroraA | ||
| ATA-3814 | NDA/BLA | CD20 | ||
| Sotozumab | Approved | PRMT5 | ||
| Doxacilimab | NDA/BLA | HER2 | ||
| Zanusotorasib | Phase 2/3 | GPRC5D | ||
| GR-8075 | Preclinical | KRASG12C | ||
| Surabrutinib | Phase 2 | RET | ||
| Elralucimab | Phase 1/2 | SOS1 | ||
| Gozesotorasib | Phase 1/2 | BET | ||
| Olpabrutinib | Phase 1/2 | KIF18A |
Trials (49)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03135374 | NVO-7840 | Phase 2/3 | Recruiting |
| NCT04354139 | Terasacituzumab | NDA/BLA | Recruiting |
| NCT07138019 | Terasacituzumab | NDA/BLA | Active |
| NCT05969738 | Ivosotorasib | Preclinical | Completed |
| NCT06048909 | ITC-1028 | Phase 2 | Terminated |
| NCT06614062 | Rilufotisoran | NDA/BLA | Terminated |
| NCT06477691 | IDY-3466 | NDA/BLA | Active |
| NCT07824638 | Motatinib | Preclinical | Active |
| NCT08820063 | 209-6556 | Preclinical | Not yet recr... |
| NCT08585196 | CHA-IIT-927 | Phase 1/2 | Completed |
| NCT06357499 | GIM-IIT-548 | Phase 3 | Terminated |
| NCT04282309 | CAR-6194 | Preclinical | Active |
| NCT08063836 | CAR-6194 | Preclinical | Active |
| NCT05603332 | INH-2936 | Phase 2 | Recruiting |
| NCT07629200 | WIN-5410 | NDA/BLA | Terminated |
| NCT04553053 | Ribozanubrutinib | Phase 2/3 | Recruiting |
| NCT08044670 | Ribozanubrutinib | Phase 2/3 | Completed |
| NCT06803906 | Gelirapivir | NDA/BLA | Active |
| NCT08972257 | DRR-2203 | Phase 2/3 | Not yet recr... |
| NCT03124065 | Gozelemzoparlimab | Approved | Not yet recr... |